Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From C.R. Bard

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Bioepis JV Sale To Provide Needed Cash To Biogen

Biogen may find itself with new business options after agreeing to sell its stake in the Samsung Bioepis biosimilars joint venture for up to $2.3bn.

Biosimilars Deals

Nine Major Approval Decisions To Watch In Early 2022

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Drug Review Companies

Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

Ophthalmic Biologics
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Davol, Inc.
    • Embo Medical Limited
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Rochester Medical, Inc.
    • Vascular Pathways, Inc.
    • FlowCardia, Inc.
    • Bridger Biomed, Inc.
UsernamePublicRestriction

Register